---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000267"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:44:06.499633+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 reduces tumor growth and metastases in aggressive TNBC models in preclinical study

## Summary
- Telomir-1 showed statistically significant reductions in primary tumor growth in two of three aggressive TNBC zebrafish xenograft models.
- In a paclitaxel-resistant model, Telomir-1 reduced tumor growth as monotherapy and in combination, and cut cancer cell spread.
- Third model (broadly treatment-resistant, ~15-25% of TNBC) showed no significant effect from Telomir-1 or paclitaxel.
- Responsive models represent ~40-60% of TNBC; company plans patient selection based on tumor biology for future trials.
- Study used BioReperia’s ZTX ONCOLEADS platform; company continues IND-enabling activities.

## SEC filing metadata
- accession: 0001493152-26-000267
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226000267/0001493152-26-000267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226000267/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000267
- JSON: https://secwatch.observer/filing/0001493152-26-000267.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.